Center for Observational Research, Amgen Ltd, Uxbridge, United Kingdom.
Center for Observational Research, Amgen Ltd, Uxbridge, United Kingdom.
Clin Colorectal Cancer. 2020 Jun;19(2):100-108.e9. doi: 10.1016/j.clcc.2020.01.001. Epub 2020 Feb 5.
This study aimed to provide a description of existing measures for the prevention and management of epidermal growth factor receptor inhibitor monoclonal antibody-induced skin toxicities and factors impacting patients' adherence to those measures in France, Germany, and Spain.
The study consisted of 2 separate surveys. Health care professionals (HCPs; oncologists and nurses) in France, Germany, and Spain were interviewed, and patients with metastatic colorectal cancer and head-and-neck cancer in France and Germany self-completed questionnaires. The study was conducted between February and July 2018.
A total of 53 oncologists, 44 nurses, and 143 patients participated in the study. HCPs stated that skin toxicities moderately (52%) or severely (28%) impacted patient care. Ninety percent of HCPs reported routine provision of prophylactic measures. The great majority of patients self-reported adherence with the prophylactic (80% to 88% depending on the type of measures) and reactive (93% to drug prescription) skin toxicity recommendations. HCPs estimated patient adherence to be 45% for full adherence and 40% for partial adherence. Most HCPs reported a positive or very positive impact of preventive measures and recommendations on skin toxicity incidence and severity, patients' quality of life, and various aspects of quality of anti-cancer treatment.
Skin toxicities are an important adversity negatively impacting on patient care. However, despite the positive perception of the effectiveness of skin toxicity prophylaxis, almost one-third of oncology centers did not provide formal guidelines, and 10% of HCPs did not provide routine prophylactic measures. Patient adherence appears to be high for epidermal growth factor receptor inhibitor monoclonal antibody-induced skin toxicity prevention measures.
本研究旨在描述目前用于预防和管理表皮生长因子受体抑制剂单克隆抗体诱导的皮肤毒性的措施，以及影响患者对这些措施的依从性的因素，该研究在法国、德国和西班牙进行。
该研究包括 2 项独立的调查。在法国、德国和西班牙采访了卫生保健专业人员（肿瘤学家和护士），并在法国和德国招募了转移性结直肠癌和头颈部癌症患者进行自我问卷调查。该研究于 2018 年 2 月至 7 月进行。
共有 53 名肿瘤学家、44 名护士和 143 名患者参与了该研究。HCPs 表示皮肤毒性对患者的护理有中度（52%）或严重影响（28%）。90%的 HCPs 报告了常规提供预防性措施。绝大多数患者自我报告了对预防性（取决于措施类型，80%至 88%）和反应性（93%至药物处方）皮肤毒性建议的依从性。HCPs 估计患者对全面和部分依从性的依从性分别为 45%和 40%。大多数 HCPs 报告预防性措施和建议对皮肤毒性的发生率和严重程度、患者的生活质量以及抗癌治疗的各个方面都有积极或非常积极的影响。
皮肤毒性是一种重要的不良事件，会对患者护理产生负面影响。然而，尽管皮肤毒性预防措施的有效性得到了积极的评价，但近三分之一的肿瘤学中心没有提供正式的指南，10%的 HCPs 没有提供常规的预防性措施。对于表皮生长因子受体抑制剂单克隆抗体诱导的皮肤毒性预防措施，患者的依从性似乎很高。
